Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy

被引:7
|
作者
Tsai, Ping-Chung [1 ]
Chien, Hung-Che [1 ]
Hsu, Po-Kuei [1 ,2 ]
Hung, Jung-Jyh [1 ,2 ]
Huang, Chien-Sheng [1 ,2 ]
Hsu, Wen-Hu [1 ,2 ]
Hsu, Han-Shui [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Div Thorac Surg, Dept Surg, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
关键词
Esophageal cancer; Oligo-recurrence; Post-recurrence survival; LYMPH-NODE RECURRENCE; SQUAMOUS-CELL CARCINOMA; OLIGOMETASTASES; CANCER; CHEMORADIOTHERAPY; OUTCOMES; METASTASECTOMY;
D O I
10.1186/s12885-022-09739-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Recurrent esophageal cancer is associated with dismal prognosis. There is no consensus about the role of surgical treatments in patients with limited recurrences. This study aimed to evaluate the role of surgical resection in patients with resectable recurrences after curative esophagectomy and to identify their prognostic factors. Methods We retrospectively reviewed patients with recurrent esophageal cancer after curative esophagectomy between 2004 and 2017 and included those with oligo-recurrence that was amenable for surgical intent. The prognostic factors of overall survival (OS) and post-recurrence survival (PRS), as well as the survival impact of surgical resection, were analyzed. Results Among 654 patients after curative esophagectomies reviewed, 284 (43.4%) had disease recurrences. The recurrences were found resectable in 63 (9.6%) patients, and 30 (4.6%) patients received surgery. The significant prognostic factors of PRS with poor outcome included mediastinum lymph node (LN) recurrence and pathologic T3 stage. In patients with and without surgical resection for recurrence cancer, the 3-year OS rates were 65.6 and 47.6% (p = 0.108), while the 3-year PRS rates were 42.9 and 23.5% (p = 0.100). In the subgroup analysis, surgery for resectable recurrence, compared with non-surgery, could achieve better PRS for patients without any comorbidities (hazard ratio 0.36, 95% CI: 0.14 to 0.94, p = 0.038). Conclusions Mediastinum LN recurrence or pathologic T3 was associated with worse OS and PRS in patients with oligo-recurrences after curative esophagectomies. No definite survival benefit was noted in patients undergoing surgery for resectable recurrence, except in those without comorbidities.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Post-recurrence survival in triple negative breast cancer.
    Morante, Zaida
    Ku, Gabriel Antonio De la Cruz
    Enriquez, Daniel
    Saavedra, Antonella
    Lujan, Maria
    Luque, Renato
    Eyzaguirre, Eduardo
    Guardamino, David
    Valcárcel, Bryan
    Araujo, Jhajaira M.
    Pinto, Joseph
    Alejandro Fuentes, Hugo
    Neciosup, Silvia P.
    Leonidas Gomez, Henry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy
    Kunisaki, Chikara
    Makino, Hirochika
    Takagawa, Ryo
    Yamamoto, Naoto
    Nagano, Yasuhiko
    Fujii, Syoichi
    Kosaka, Takashi
    Ono, Hidetaka A.
    Otsuka, Yuichi
    Akiyama, Hirotoshi
    Ichikawa, Yasushi
    Shimada, Hiroshi
    JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (05) : 802 - 810
  • [43] Surgical Outcomes in Esophageal Cancer Patients with Tumor Recurrence After Curative Esophagectomy
    Chikara Kunisaki
    Hirochika Makino
    Ryo Takagawa
    Naoto Yamamoto
    Yasuhiko Nagano
    Syoichi Fujii
    Takashi Kosaka
    Hidetaka A. Ono
    Yuichi Otsuka
    Hirotoshi Akiyama
    Yasushi Ichikawa
    Hiroshi Shimada
    Journal of Gastrointestinal Surgery, 2008, 12 : 802 - 810
  • [44] Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
    Jiang, Kuikui
    Zhou, Danyang
    Xu, Fei
    Xia, Wen
    Zheng, Qiufan
    Lu, Qianyi
    Luo, Rongzhen
    Hong, Ruoxi
    Wang, Shusen
    BMC CANCER, 2023, 23 (01)
  • [45] Oligo-recurrence on tyrosine kinase inhibitors: is radiotherapy an option?
    Davies, R. S.
    Bowden, C.
    Nelmes, D.
    Butler, R.
    Lester, J. F.
    LUNG CANCER, 2015, 87 : S28 - S29
  • [46] Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients with Driver Mutations
    Tachibana, Taimei
    Matsuura, Yosuke
    Ninomiya, Hironori
    Ichinose, Junji
    Nakao, Masayuki
    Okumura, Sakae
    Nishio, Makoto
    Ikeda, Norihiko
    Mun, Mingyon
    CANCERS, 2024, 16 (02)
  • [47] Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy
    Niibe, Yuzuru
    Hayakawa, Kazushige
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (02) : 107 - 111
  • [48] Post-recurrence survival after liver transplantation for hepatocellular carcinoma: outcomes of an "orphan" disease
    Maspero, Marianna
    Sposito, Carlo
    Bongini, Marco
    Bhoori, Sherrie
    Bellia, Valentina
    Schlegel, Andrea
    Mazzaferro, Vincenzo
    JOURNAL OF HEPATOLOGY, 2024, 80 : S375 - S375
  • [49] Novel Insights of Oligometastases and Oligo-Recurrence and Review of the Literature
    Niibe, Yuzuru
    Chang, Joe Y.
    PULMONARY MEDICINE, 2012, 2012
  • [50] Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
    Tabata, Ken-ichi
    Niibe, Yuzuru
    Satoh, Takefumi
    Tsumura, Hideyasu
    Ikeda, Masaomi
    Minamida, Satoru
    Fujita, Tetsuo
    Ishii, Daisuke
    Iwamura, Masatsugu
    Hayakawa, Kazushige
    Baba, Shiro
    PULMONARY MEDICINE, 2012, 2012